No Data
No Data
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Flamingo Therapeutics Announces First Patients Dosed in the United Kingdom and Korea in Ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary
Ionis Pharmaceuticals: A Strong Buy on Robust R&D and Promising Pipeline Developments
The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Ionis Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
No Data